Food Safety Incidents

Inaccurate Labeling has been detected in Major bupleurum teapills.

Written by SGS Digicomply Editorial Team | Jul 29, 2025 10:00:00 PM

On July 10, 2025, the U.S. Food and Drug Administration reported an incident concerning the inaccurate labeling of Major bupleurum teapills. This incident falls under the category of control and has been classified as a labeling hazard.

The source of the issue is traced back to China, where the teapills are produced. Inaccurate labeling can lead to significant concerns regarding consumer safety, as it may result in misinformation about the product's contents, usage instructions, or potential allergens.

The FDA’s alert highlights the importance of accurate product labeling in maintaining public health standards. Consumers are advised to be vigilant and verify product information, especially when discrepancies arise in labeling practices. The incident underscores the critical nature of regulatory oversight in ensuring that health products meet safety and efficacy standards.

As the situation develops, further investigations may be conducted to assess the extent of the labeling inaccuracies and implement necessary corrective actions. The implications of such incidents can have widespread effects on consumer trust and product integrity.

  • Incident: Inaccurate Labeling has been detected in Major bupleurum teapills.
  • Date: 2025-07-10
  • Product: Major bupleurum teapills
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: China
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Hazard Category: Labelling
  • Source: U.S. Food and Drug Administration